A COVID-19 vaccine that can be produced locally in low-income and middle-income countries is yielding promising results in early clinical trials, researchers say. Other researchers believe that once the body has been “primed” by mRNA vaccines to recognize and attack the coronavirus, a booster containing purified versions of virus’ spike protein that could be given intranasally would have many advantages.
A follow-up study of 33 people who received Moderna Inc.’s Covid-19 vaccine in early trials show the antibodies it induced are still present six months after the second dose.
In a study published in Nature Medicine, scientists at Columbia University and Vanderbilt University describe how they were able to successfully restore badly damaged lungs in order to use them for lung transplants.
A 17-year-old Michigan boy facing “imminent death” from vaping injuries underwent a double lung transplant, the first in a patient suffering from the effects of e-cigarettes.
